Literature DB >> 2158755

Identification of monoclonal antibodies capable of differentiating antigenic varieties of eastern equine encephalitis viruses.

J T Roehrig1, A R Hunt, G J Chang, B Sheik, R A Bolin, T F Tsai, D W Trent.   

Abstract

We have isolated and characterized 3 monoclonal antibody (Mab) reagents useful in the serological identification of varieties of eastern equine encephalitis (EEE) viruses. These antibodies were specific for the E1 glycoprotein of their homologous viruses. One Mab, 1B5C-3, reacted specifically with all North American (NA) EEE viruses isolated over a 50 year period. This antigenic stability of NA isolates was genetically confirmed by oligonucleotide fingerprinting. Evolutionary stability is a unique feature among alphaviruses. The Mab, 1C1J-4 reacted specifically with 1 South American isolate of EEE virus. A third Mab, 1B1C-4, was EEE virus complex reactive. While none of these antibodies had virus neutralizing activity, the identified reactivities could be demonstrated in the more rapid serological tests of enzyme-linked immunosorbent assay and indirect immunofluorescence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158755     DOI: 10.4269/ajtmh.1990.42.394

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  25 in total

1.  Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay.

Authors:  A J Johnson; D A Martin; N Karabatsos; J T Roehrig
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

2.  Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies.

Authors:  Brett A Thibodeaux; Nathan M Liss; Amanda N Panella; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

3.  Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies.

Authors:  Brett A Thibodeaux; Amanda N Panella; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

4.  Use of a new synthetic-peptide-derived monoclonal antibody to differentiate between vaccine and wild-type Venezuelan equine encephalomyelitis viruses.

Authors:  J T Roehrig; R A Bolin; A R Hunt; T M Woodward
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

5.  Removal of species constraints in antibody detection.

Authors:  Alison Jane Basile; Brad J Biggerstaff; Olga L Kosoy; Shilpa R Junna; Nicholas A Panella; Ann M Powers; Lillian M Stark; Nicole M Nemeth
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

6.  Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies.

Authors:  Jason Porta; Joyce Jose; John T Roehrig; Carol D Blair; Richard J Kuhn; Michael G Rossmann
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype 1 Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay.

Authors:  J T Roehrig; R A Bolin
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

Review 8.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

9.  Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus.

Authors:  Patricia V Aguilar; Slobodan Paessler; Anne-Sophie Carrara; Samuel Baron; Joyce Poast; Eryu Wang; Abelardo C Moncayo; Michael Anishchenko; Douglas Watts; Robert B Tesh; Scott C Weaver
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence.

Authors:  Patricia V Aguilar; A Paige Adams; Eryu Wang; Wenli Kang; Anne-Sophie Carrara; Michael Anishchenko; Ilya Frolov; Scott C Weaver
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.